Our Pipeline | ImmunoGen for ADC Technology-focused Cancer Treatment

Our

Pipeline

We bring more than 35 years of innovation to the ADC field. Our lead program, mirvetuximab soravtansine, is a first-in-class ADC in Phase 3 development for platinum-resistant ovarian cancer and we have a number of ADCs in development in our clinical and early stage pipelines.

Compound

Preclinical Research

Preclinical Development

Phase 1

Phase 2

Phase 3

Mirvetuximab Soravtansine

TARGET: Anti-FRa ADC

SORAYA: Monotherapy in FRa-High Platinum-Resistant Ovarian Cancer (Single-Arm Pivotal Trial)

MIRASOL: Monotherapy in FRa-High Platinum-Resistant Ovarian Cancer (Randomized Confirmatory Trial)

FORWARD II: Doublet with AVASTIN® Triplet with AVASTIN® and Carboplatin in Recurrent Ovarian Cancer

IMGN632

TARGET: Anti-CD123 ADC

801: Monotherapy in BPDCN (Includes Single-Arm Pivotal Cohort in Frontline)

802: Doublet with VIDAZA® and VENCLEXTA® and as a Triplet in AML

802: Monotherapy in MRD+ AML

IMGN151

TARGET: Anti-FRa Biparatopic ADC

Ovarian, Endometrial, NSCLC, and TNBC

IMGC936

TARGET: Anti-ADAM9 ADC

NSCLC, Gastric, Pancreatic, TNBC, and Other Solid Tumors

Solid Tumor Heme Malignancies

partnerships

In addition to our own, proprietary pipeline of ADC candidates, we have a number of partnerships and collaborations in place that leverage our technology – and those of our collaborators – to address unmet medical needs. We continually seek innovative partnerships with the goal of advancing science, gaining access to complimentary capabilities, strengthening our financial position, and creating more value for ImmunoGen.

Examples of our partnerships include a strategic cross-licensing agreement with CytomX Therapeutics to develop ProbodyTM drug conjugate (PDC) therapies and a co-development and co-promotion collaboration with MacroGenics to develop a first-in-class ADAM9-targeting ADC.

legacy platform deals

Our technology platform has been the basis for a number of high-value partnerships for the company, including the first-ever ADC approved as a treatment option for HER2-positive breast cancer, which is marketed by Roche, called Kadcyla®.

In addition to Roche, we have ADC technology deals in place with Amgen, Bayer, and Sanofi.